New drug applications approved by US FDA as of 1 - 15 July 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Over three-quarter of Singaporean patients with obstructive sleep apnoea (OSA) who were adherent and took on continuous positive airway pressure (CPAP) therapy after a 1-month CPAP trial period continued to be adherent to the therapy at 1 year, indicating that initial receptibility to CPAP is predictive of long-term adherence to the therapy, a local study finds.
Respiratory infections, particularly influenza, may increase the risk of treatment failure in children with asthma who present to emergency departments (EDs) with exacerbations, a secondary analysis of the DOORWAY* study revealed.
Higher doses of rifampin result in more rapid sputum sterilization and similar toxicity, a study has shown. These findings support the investigation of increased rifampin doses to shorten tuberculosis treatment.
Combining a long-acting beta-agonist (LABA) with an inhaled corticosteroid (ICS) did not lead to a higher risk of serious asthma-related events compared with ICS alone, according to a combined analysis of four large FDA-mandated postmarketing safety trials.
Fluticasone furoate is superior to mometasone nasal spray in improving several perceived sensory attributes of allergic rhinitis patients, based on a multicentre, randomised, crossover, prospective study.
In children and adolescents with cystic fibrosis (CF), synbiotic supplementation appears to be effective at reducing proinflammatory markers such as interleukin (IL)-6 and -8, and nitric oxide metabolites (NOx), a recent study has found.